Sign Up for Free!

Continue Analyzing the page and more.

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Ticker Image

Avadel Pharmaceuticals PLC

US$0

US$859.6m

-2.0%

46.8%

Ticker Image

Avadel Pharmaceuticals PLC

US$0

US$859.6m

-2.0%

46.8%

Overview Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Ratio
Dashboard Funda..tals Deep..lue Prediction Screener Map

Avadel Pharmaceuticals PLC Overview

Industry: Drug Manufacturers Specialty & Generic

Sector: Healthcare

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland. Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company w Read More

Avadel Pharmaceuticals PLC is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

Avadel Pharmaceuticals PLC

Score

Recent News



Earnings Per Share

Score 3.00/5
Avadel Pharmaceuticals PLC boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc UnitedHealth Group Incorporated IQVIA Holdings Inc
In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , SIGA Technologies Inc , Prestige Consumer Healthcare are companies with high ratings.

Return on Equity

Score 0.38/5
Avadel Pharmaceuticals PLC exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc UnitedHealth Group Incorporated IQVIA Holdings Inc

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , SIGA Technologies Inc , Prestige Consumer Healthcare are companies with high ratings.

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

Net Margin

Score 1.15/5
Avadel Pharmaceuticals PLC olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc UnitedHealth Group Incorporated IQVIA Holdings Inc

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , SIGA Technologies Inc , Prestige Consumer Healthcare are companies with high ratings.

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

Share Buyback

In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , SIGA Technologies Inc , Prestige Consumer Healthcare are companies with high ratings.

Leverage

Score 1.67/5
Avadel Pharmaceuticals PLC registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc UnitedHealth Group Incorporated IQVIA Holdings Inc have achieved high scores.

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , SIGA Technologies Inc , Prestige Consumer Healthcare are companies with high ratings.

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

Financial Ratio

Yearly Quarterly

Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios